Impact of Atrial Fibrillation on Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): The K-TAVI Registry
Sang Yoon Lee, Ki Hong Choi, Taek Kyu Park, Jihoon Kim, Eun Kyoung Kim, Sung‐Ji Park, Seung Woo Park, Hyeon‐Cheol Gwon, Kiyuk Chang, Cheol Woong Yu, Ju Han Kim, Young Jin Choi, In-Ho Chae, Jae-Hwan Lee, Junhong Kim, J Park, Won‐Jang Kim, Young Won Yoon, Tae Hoon Ahn, Sang Rok Lee, Byoung‐Joo Choi, Tae‐Hyun Yang, Cheol Ung Choi, Seung‐Ho Hur, Seong Jin Oh, Han Cheol Lee, Hun Sik Park, Hyo-Soo Kim, Seung‐Hyuk Choi
Abstract
PURPOSE: The incidence and prognostic implications of atrial fibrillation (AF) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) are controversial, especially for Korean patients. Furthermore, the pattern of antithrombotic therapy for these patients is unknown. The present study sought to identify the impact of AF on Korean patients undergoing TAVI and demonstrate the status of antithrombotic therapy for these patients. MATERIALS AND METHODS: A total of 660 patients who underwent TAVI for severe AS were recruited from the nationwide K-TAVI registry in Korea. The enrolled patients were stratified into sinus rhythm (SR) and AF groups. The primary endpoint was all-cause death at 1-year. RESULTS: =0.001). Among AF patients, substantial number of patients received the combination of multiple antithrombotic agents (77.8%), and the most common combination was that of aspirin and clopidogrel (38.1%). CONCLUSION: AF was an independent predictor of 1-year mortality and new pacemaker insertion in Korean patients undergoing TAVI.